[1]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]
[2]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]
[3]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]
[4]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]
[1]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]
[1]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]
[2]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]
[1]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]
Title: Cortes J, et al. Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. Blood 2008 112:3232
Title: Douglas O, et al. Abstract C192: Characterization of the target profile of XL228, a multi‐targeted protein kinase inhibitor in phase 1 clinical development. Mol Cancer Ther 2009;8(12 Suppl):C192.
Title: Shah N, et al. Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228. Blood 2007 110:474;